Knopp Neurosciences Reports Presentation Of Encouraging Clinical Trends In A Phase 2 Study Of KNS-760704 In ALS

Knopp Neurosciences Inc. ("Knopp") announced the presentation of encouraging clinical results in a Phase 2 safety and tolerability study of KNS-760704 in amyotrophic lateral sclerosis ("ALS"). The results were presented at the 20th International Symposium on ALS/MND in Berlin, Germany, by Merit Cudkowicz, M.D...
This entry was posted in News from Other Sources. Bookmark the permalink. Both comments and trackbacks are currently closed.